(NASDAQ: RARE) Ultragenyx Pharmaceutical's forecast annual revenue growth rate of 23.26% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.94%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.52%.
Ultragenyx Pharmaceutical's revenue in 2024 is $434,249,000.On average, 9 Wall Street analysts forecast RARE's revenue for 2024 to be $42,338,574,633, with the lowest RARE revenue forecast at $41,176,900,426, and the highest RARE revenue forecast at $43,638,737,467. On average, 9 Wall Street analysts forecast RARE's revenue for 2025 to be $50,385,076,653, with the lowest RARE revenue forecast at $44,603,711,719, and the highest RARE revenue forecast at $58,399,879,432.
In 2026, RARE is forecast to generate $69,522,442,718 in revenue, with the lowest revenue forecast at $56,866,788,940 and the highest revenue forecast at $86,026,795,848.